NO20031521D0 - Association of CB1 Receptor Antagonist and a Sibutramine, Pharmaceutical Preparations Containing It and Its Use in the Treatment of Obesity - Google Patents

Association of CB1 Receptor Antagonist and a Sibutramine, Pharmaceutical Preparations Containing It and Its Use in the Treatment of Obesity

Info

Publication number
NO20031521D0
NO20031521D0 NO20031521A NO20031521A NO20031521D0 NO 20031521 D0 NO20031521 D0 NO 20031521D0 NO 20031521 A NO20031521 A NO 20031521A NO 20031521 A NO20031521 A NO 20031521A NO 20031521 D0 NO20031521 D0 NO 20031521D0
Authority
NO
Norway
Prior art keywords
association
receptor antagonist
obesity
sibutramine
treatment
Prior art date
Application number
NO20031521A
Other languages
Norwegian (no)
Other versions
NO20031521L (en
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20031521(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20031521D0 publication Critical patent/NO20031521D0/en
Publication of NO20031521L publication Critical patent/NO20031521L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention concerns the association of the CB1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity.
NO20031521A 2000-10-04 2003-04-03 Association of CB1 Receptor Antagonist and a Sibutramine, Pharmaceutical Preparations Containing It and Its Use in the Treatment of Obesity NO20031521L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (en) 2000-10-04 2000-10-04 COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
PCT/FR2001/003022 WO2002028346A2 (en) 2000-10-04 2001-10-01 Association of the cb1 receptor antagonist and sibutramin, for treating obesity

Publications (2)

Publication Number Publication Date
NO20031521D0 true NO20031521D0 (en) 2003-04-03
NO20031521L NO20031521L (en) 2003-04-24

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031521A NO20031521L (en) 2000-10-04 2003-04-03 Association of CB1 Receptor Antagonist and a Sibutramine, Pharmaceutical Preparations Containing It and Its Use in the Treatment of Obesity

Country Status (29)

Country Link
EP (1) EP1328269B2 (en)
JP (1) JP4221221B2 (en)
KR (1) KR20030036885A (en)
CN (1) CN100409845C (en)
AT (1) ATE267595T1 (en)
AU (2) AU2001293936B2 (en)
BG (1) BG107739A (en)
BR (1) BR0114410A (en)
CA (1) CA2424934A1 (en)
DE (1) DE60103556T3 (en)
DK (1) DK1328269T5 (en)
EA (1) EA005924B1 (en)
EE (1) EE200300121A (en)
ES (1) ES2217191T5 (en)
FR (1) FR2814678B1 (en)
HR (1) HRP20030249A2 (en)
HU (1) HUP0302044A3 (en)
IL (1) IL155236A0 (en)
MX (1) MXPA03002845A (en)
NO (1) NO20031521L (en)
NZ (1) NZ524904A (en)
PL (1) PL362833A1 (en)
PT (1) PT1328269E (en)
SI (1) SI1328269T2 (en)
SK (1) SK4032003A3 (en)
TR (1) TR200401264T4 (en)
WO (1) WO2002028346A2 (en)
YU (1) YU26103A (en)
ZA (1) ZA200303015B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (en) * 2001-12-21 2004-02-13 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS BASED ON AZETIDINE DERIVATIVES
ATE486842T1 (en) 2002-03-12 2010-11-15 Merck Sharp & Dohme SUBSTITUTED AMIDES
CA2479618A1 (en) 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc Bicyclic amides
MXPA05000962A (en) 2002-07-29 2005-05-16 Hoffmann La Roche Novel benzodioxoles.
CA2511859A1 (en) 2003-01-02 2004-07-22 Alexander Mayweg Novel cb 1 receptor inverse agonists
EP1583762B1 (en) 2003-01-02 2008-07-09 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
NZ543451A (en) 2003-06-11 2008-08-29 Merck & Co Inc Substituted 3-alkyl and 3-alkenyl azetidine derivitives
EP1638556B1 (en) 2003-06-20 2008-04-02 F. Hoffmann-La Roche Ag 2-aminobenzothiazoles as cb1 receptor inverse agonists
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
RU2006110545A (en) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) NEW MEDICAL APPLICATION OF SELECTIVE ANTAGONISTS CB1-RECEPTOR
FR2861303A1 (en) * 2003-10-24 2005-04-29 Sanofi Synthelabo Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
CA2547804A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivatives
DE602005023124D1 (en) 2004-01-28 2010-10-07 Hoffmann La Roche SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS
ES2324720T3 (en) 2004-05-10 2009-08-13 F. Hoffmann-La Roche Ag PIRROL OR IMIDAZOL AMIDAS TO TREAT OBESITY.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007003732A (en) * 2004-09-29 2007-04-23 Schering Corp Combinations of substituted azetidonones and cb1 antagonists.
FR2876689B1 (en) * 2004-10-14 2008-02-22 Aventis Pharma Sa NOVEL PROCESS AND INTERMEDIATES FOR PREPARING N- (1-BENZHYDRYL-AZETIDIN-3-YL) -N-PHENYL-METHYLSULFONAMIDE DERIVATIVES
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
MX2007004910A (en) 2004-10-27 2007-06-14 Hoffmann La Roche New indole or benzimidazole derivatives.
JP4675969B2 (en) 2004-11-09 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー Dibenzosuberone derivatives
EP1868999B1 (en) 2005-04-06 2009-07-01 F. Hoffmann-Roche AG Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
JP2009528999A (en) * 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド CB1 antagonists and inverse agonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
WO2008026219A2 (en) * 2006-09-01 2008-03-06 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
BRPI0718515A2 (en) * 2006-09-25 2013-11-19 Boehringer Ingelheim Int COMPOUNDS THAT MODULATE THE CB2 RECEIVER
DE102007002260A1 (en) 2007-01-16 2008-07-31 Sanofi-Aventis Use of substituted pyranonic acid derivatives for the preparation of medicaments for the treatment of the metabolic syndrome
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009106708A2 (en) * 2007-12-18 2009-09-03 Sanofi-Aventis Azetidine derivatives, their preparation and their application in therapy
WO2010079241A1 (en) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
BRPI0902481B8 (en) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes pharmaceutical composition comprising hemopressin and its use.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (en) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp Proximity electrifier
FR2713225B1 (en) † 1993-12-02 1996-03-01 Sanofi Sa Substituted N-piperidino-3-pyrazolecarboxamide.
JPH07209959A (en) * 1994-01-24 1995-08-11 Ricoh Co Ltd Electrostatic charging device
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (en) * 1995-06-21 1997-09-12 Sanofi Sa USE OF HUMAN CB2 RECEPTOR AGONIST COMPOUNDS FOR THE PREPARATION OF IMMUNOMODULATORY DRUGS, NOVEL CB2 RECEPTOR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
CA2269660A1 (en) † 1996-10-31 1998-05-07 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (en) * 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
US6153524A (en) * 1997-07-29 2000-11-28 Silicon Genesis Corporation Cluster tool method using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
KR100652994B1 (en) † 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (en) * 1998-09-11 2000-11-17 Aventis Pharma Sa AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
FR2805817B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION
FR2805810B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION

Also Published As

Publication number Publication date
ES2217191T5 (en) 2009-02-16
ES2217191T3 (en) 2004-11-01
EP1328269B2 (en) 2008-07-30
CN100409845C (en) 2008-08-13
CA2424934A1 (en) 2002-04-11
EP1328269A2 (en) 2003-07-23
JP2004512279A (en) 2004-04-22
AU2001293936B2 (en) 2007-01-25
HRP20030249A2 (en) 2005-02-28
SI1328269T1 (en) 2004-10-31
IL155236A0 (en) 2003-11-23
JP4221221B2 (en) 2009-02-12
EA200300441A1 (en) 2003-08-28
DK1328269T3 (en) 2004-09-20
WO2002028346A2 (en) 2002-04-11
WO2002028346A3 (en) 2002-08-29
SK4032003A3 (en) 2003-09-11
AU9393601A (en) 2002-04-15
DK1328269T4 (en) 2008-11-24
CN1473040A (en) 2004-02-04
PT1328269E (en) 2004-08-31
DE60103556D1 (en) 2004-07-01
NZ524904A (en) 2004-11-26
HUP0302044A3 (en) 2005-05-30
DE60103556T3 (en) 2009-04-09
FR2814678B1 (en) 2002-12-20
TR200401264T4 (en) 2004-07-21
ATE267595T1 (en) 2004-06-15
EE200300121A (en) 2005-04-15
HUP0302044A2 (en) 2003-11-28
DE60103556T2 (en) 2005-06-30
YU26103A (en) 2006-08-17
NO20031521L (en) 2003-04-24
BG107739A (en) 2004-01-30
DK1328269T5 (en) 2009-03-16
ZA200303015B (en) 2004-02-26
EA005924B1 (en) 2005-08-25
PL362833A1 (en) 2004-11-02
BR0114410A (en) 2004-02-17
KR20030036885A (en) 2003-05-09
EP1328269B1 (en) 2004-05-26
SI1328269T2 (en) 2008-12-31
FR2814678A1 (en) 2002-04-05
MXPA03002845A (en) 2004-09-10

Similar Documents

Publication Publication Date Title
NO20031521D0 (en) Association of CB1 Receptor Antagonist and a Sibutramine, Pharmaceutical Preparations Containing It and Its Use in the Treatment of Obesity
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
BR0309665A (en) Treatment of alpha-galactosidase deficiency at
DE60007095T2 (en) CALANOLIDE FOR INHIBITING BTK
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
BR0116452A (en) Compound, pharmaceutical composition, use of a compound
DE69905170T2 (en) THIAZOLOPYRIMIDINDERIVATE
RS20050132A (en) Use of cgrp antagonist compounds for treatment of psoriasis
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
TNSN06202A1 (en) Anticorps agonistes inti-trkc et procedes qui les utilisent
MY137620A (en) Therapeutic treatment
DE69907926D1 (en) 1,2,4-TRIAZOL-3-THION COMPOUNDS
DE69917230D1 (en) COMBINATION PRODUCT CONTAINING SELECTIVE NMDA NR2B ANTAGONISTS AND COX-2 INHIBITORS
NO20035602D0 (en) A composition comprising a PDE-4 inhibitor and H1 receptor antagonist, as well as its use in the preparation of a medicament for the treatment of respiratory diseases.
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
NO20000519L (en) 2-acylaminopropanamines as tachykinin receptor antagonists
DE60130659D1 (en) THERAPEUTIC COMPOUNDS AND METHOD
DK1420789T3 (en) Use of active substances with myopioid receptor agonist and opioid receptor antagonist effect as combination drugs for cancer treatment
MXPA04005226A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof.
MXPA01009174A (en) New pyridazine endothelin antagonists.
GB0228699D0 (en) Novel therapeutic target

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application